Ross L Levine MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Join to view full profile
530 East 74th StreetNew York, NY 10021
Dr. Levine is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
Johns Hopkins University School of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2021 - 2027
NY State Medical License 2007 - 2026
MA State Medical License 2001 - 2008
American Board of Internal Medicine Hematology
Clinical Trials
- Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia Start of enrollment: 2011 Aug 17
Publications & Presentations
PubMed
- Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, Deedra Nicolet, Krzysztof Mrózek
American Journal of Hematology. 2026-09-01 - Stromal cell senescence augments haematopoietic cell fitness in clonal haematopoiesis.Jayna J Mistry, Kira A Young, Anna Navarro Figueredo, Gibran Edun, Alicia G Aguilar-Navarro
Nature Cell Biology. 2026-08-01 - Reinventing biotech systems for patient impact.Kushal T Kadakia, Yashodhara Dash, Amy P Abernethy, Nicholaas Honig, Ross L Levine
Nature Medicine. 2026-08-01
Press Mentions
Penn Medicine Princeton Health Breaks Ground on $401M Cancer CenterOctober 20th, 2025- 54 Cardio-Oncology Centers of ExcellenceOctober 20th, 2025
- Indiana System Partners with Notre Dame on Cancer ResearchOctober 17th, 2025
Grant Support
- Clonal hematopoiesis as a targetable mechanism of resistance to therapy in thyroid cancer.SLOAN-KETTERING INST CAN RESEARCH2026–2031
- Synergistic role of signaling and epigenetics in leukemic transformationSLOAN-KETTERING INST CAN RESEARCH2017–2030
- ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)SLOAN-KETTERING INST CAN RESEARCH2025–2026
- Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia InitiationJACKSON LABORATORY2021–2026
- Role of TET2 mutations in malignant transformation and acute myeloid leukemiaSLOAN-KETTERING INST CAN RESEARCH2013–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
